Dosing

Start patients on a seamless dosing pathway to INVEGA TRINZA® after initiating stabilization with INVEGA SUSTENNA® today1*

 
  • INVEGA TRINZA® (paliperidone palmitate) is to be used only after the 1-month paliperidone palmitate extended-release injectable suspension (INVEGA SUSTENNA®) has been established as adequate treatment for at least 4 months1*
  • In order to establish a consistent maintenance dose, it is recommended that the last 2 doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®1
  • For those who have not taken oral paliperidone, oral risperidone, or injectable risperidone previously, establish tolerability with oral paliperidone or oral risperidone before starting INVEGA SUSTENNA®2

*Based on your evaluation of the patient's response.

Chart

When patients are ready to transition to INVEGA TRINZA®1

  • Following the initial INVEGA TRINZA® dose, INVEGA TRINZA® should be administered once every 3 months
  • If needed, dose adjustments can be made every 3 months in increments within the range of 273 mg to 819 mg based on tolerability or efficacy
    –Due to the long-acting nature of INVEGA TRINZA®, the patient's response to an adjusted dose may not be apparent for several months
  • Between doses, patients can maintain scheduled treatment plans and routine interactions with their treatment team

You can seamlessly transition your patients to INVEGA TRINZA® after they have been adequately treated with INVEGA SUSTENNA® for at least 4 months1

Chart

Renal impairment1

  • INVEGA TRINZA® (paliperidone palmitate) has not been studied in patients with renal impairment
  • For patients with mild renal impairment (creatinine clearance ≥50 mL/min to <80 mL/min [Cockcroft-Gault formula]), adjust dosage and stabilize the patient using the 1-month paliperidone palmitate extended-release injectable suspension, then transition to INVEGA TRINZA®
  • INVEGA TRINZA® is not recommended in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min)

Pregnancy1

  • Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery
  • There are no available data on INVEGA TRINZA® use in pregnant women to inform any drug-associated risks for birth defects or miscarriages
  • Paliperidone has been detected in plasma at very low levels up to 18 months after a single-dose administration of INVEGA TRINZA®, and the clinical significance of INVEGA TRINZA® administered before pregnancy or anytime during pregnancy is not known
  • Advise pregnant women of the potential risks to a fetus. The background risks of major birth defects and miscarriages for the indicated population are unknown. In the US general population, the estimated background risks of major birth defects and miscarriages in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively

Nursing1

  • Paliperidone is present in human breast milk; however, there are insufficient data to assess the amount in human milk, the effects in the breast-fed infant, or the effects on milk production
  • Paliperidone has been detected in plasma at very low levels up to 18 months after a single-dose administration of INVEGA TRINZA®, and the clinical significance in the breast-fed infant is not known

What to do when a dose is missed1

INVEGA TRINZA® (paliperidone palmitate) is administered once every 3 months. Missing doses should be avoided.1

References: 1. INVEGA TRINZA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2016. 2. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2016.